Cancer Vaccine Consortium Engages Regulatory Process:

Sabin's picture Submitted by Sabin on

NEW CANAAN, CT, April 7, 2004—The regulation of cancer vaccines by the U.S. Food and Drug Administration (FDA) and European Union offers both opportunities and potential pitfalls for industry and research, according to speakers at last week’s meeting of the Cancer Vaccine Consortium (CVC), “Federal Regulation and Cancer Vaccines.” As part of the meeting, the CVC launched two new working groups to address regulatory issues and engage the FDA in policy discussions.

Former CDC Immunization Program Director Joins Board of Sabin Vaccine Institute

Sabin's picture Submitted by Sabin on

NEW CANAAN, CT—The Board of Trustees of the Albert B. Sabin Vaccine Institute announced the election of their newest board member, Walter Orenstein, MD. Recently recruited as Professor of Medicine and Pediatrics at Emory University School of Medicine, Dr. Orenstein’s posts at Emory will include director of the Program for Vaccine Policy and Development and associate director of the Vaccine Center. Dr.

Researchers to Meet on Cutting-edge Cancer Vaccine Development at 2004 Colloquium on Cancer Vaccines and Immunotherapy

Sabin's picture Submitted by Sabin on

NEW CANAAN, CT— Approximately forty of the world’s leading cancer vaccine researchers will meet this week at a scientific colloquium organized by the Albert B. Sabin Vaccine Institute. Convening in think-tank sessions, they will report on the latest developments in this promising field of therapy focused on stimulation of the body’s immune system to attack existing cancerous cells.

Sabin Institute Board Appoints President and CEO:

Sabin's picture Submitted by Sabin on

NEW CANAAN, CT, March 29, 2004—The Board of Trustees of the Albert B. Sabin Vaccine Institute is pleased to announce the appointment of Dean D. Mason as its new president and chief executive officer. The appointment is effective April 7, 2004. “We look forward to Mr. Mason’s leadership of the Institute at this important time in the organization’s evolution,” said Board chairman H.R. Shepherd.

Pages